Media of Health Research
Vol. 3 No. 2, August 2025, pages: 32-40
e-ISSN 2987-7784
DOI: https://doi.org/10.70716/mohr.v3i2.203

Effectiveness of Combination Antihypertensive Therapy for Controlling Blood Pressure in the Elderly

Abdullah Taufiqurrahman[1*], Elijah Alexander[2]
[1] D3 Rekam Medis & Informasi Kesehatan, Universitas Qamarul Huda Badaruddin (UNIQHBA), Lombok Tengah, Indonesia
[2] Bachelor of Science in Nursing, Singapore Institute of Technology, Singapore
**Corresponding Author: Taufiq12@gmail.com*

Article History

Manuscript submitted:
10 June 2025
Manuscript revised:
26 August 2025
Accepted for publication:
30 August 2025

Keywords

hypertension
elderly
combination therapy
blood pressure control
antihypertensive drugs

Abstract

Background: Hypertension is a prevalent condition among the elderly and a major risk factor for cardiovascular morbidity and mortality. Monotherapy often fails to achieve optimal blood pressure (BP) control in this population due to age-related physiological changes and comorbidities. Objective: This study aims to evaluate the effectiveness of combination antihypertensive therapy in achieving blood pressure control among elderly patients. Methods: A retrospective cohort study was conducted involving elderly patients (≥65 years) diagnosed with hypertension and receiving combination antihypertensive therapy. Blood pressure measurements were assessed at baseline and after 3 months of treatment. The primary outcome was the proportion of patients achieving target BP (<140/90 mmHg). Secondary outcomes included changes in systolic and diastolic BP and incidence of adverse effects. Results: Among 210 participants, 72.4% achieved target BP after 3 months of combination therapy. The mean reduction in systolic and diastolic BP was 18.6 ± 6.2 mmHg and 9.3 ± 3.8 mmHg, respectively. Combination therapy was generally well tolerated, with minimal adverse events reported. Conclusion: Combination antihypertensive therapy is effective and well tolerated in controlling blood pressure among the elderly. Its use should be considered in patients who do not achieve target BP with monotherapy, with close monitoring for potential side effects.

How to Cite: Taufiqurrahman, A. & Alexander, E. (2025). Effectiveness of Combination Antihypertensive Therapy for Controlling Blood Pressure in the Elderly. *Media of Health Research, 3*(2), 32-40. https://doi.org/10.70716/mohr.v3i2.203

Introduction

Hypertension, commonly referred to as high blood pressure, is one of the most prevalent chronic conditions worldwide and is especially common among the elderly population. It poses a major public health challenge due to its strong association with cardiovascular diseases such as stroke, myocardial infarction, heart failure, and chronic kidney disease. With the aging of populations globally, the burden of hypertension among older adults is expected to rise significantly in the coming decades, necessitating more effective and tailored management strategies (Mills et al, 2020).

In elderly individuals, hypertension is not only more prevalent but also presents with unique physiological and clinical characteristics. Age-related changes in vascular compliance, endothelial function, and renal sodium handling all contribute to increased systolic blood pressure and widened pulse pressure. These changes often lead to isolated systolic hypertension, a condition that is particularly difficult to manage and is associated with elevated cardiovascular risk (Oliveroset al, 2020). The control of blood pressure in older adults presents specific challenges. Elderly patients frequently have comorbidities such as diabetes, chronic kidney disease, and cognitive impairment, which complicate treatment decisions. Moreover, the pharmacokinetics and pharmacodynamics of antihypertensive medications can be altered in older adults, increasing the risk of adverse drug reactions, orthostatic hypotension, and falls (Whelton et al, 2018).

Despite the known risks associated with uncontrolled hypertension in older adults, blood pressure control rates remain suboptimal in this population. Studies have shown that monotherapy often fails to achieve adequate BP control in elderly patients, prompting interest in the use of combination therapy as a potentially more effective approach. Combination antihypertensive therapy involves the use of two or more antihypertensive agents with different mechanisms of action. This strategy offers several advantages, including improved BP-lowering efficacy, the potential to use lower doses of individual drugs (thereby minimizing side effects), and the ability to target different pathophysiological aspects of hypertension (Weber et al, 2014).

Several major guidelines, including those from the American College of Cardiology (ACC), American Heart Association (AHA), and the European Society of Hypertension (ESH), now recommend initiating combination therapy in patients with markedly elevated blood pressure or those unlikely to achieve target levels with monotherapy alone. However, data on the effectiveness and safety of such an approach specifically in elderly populations remain limited. The use of combination therapy in the elderly must be carefully considered, balancing the need for effective BP control with the risk of adverse effects. Polypharmacy is a major concern in geriatric medicine, and the addition of multiple antihypertensive agents can contribute to medication burden, drug interactions, and nonadherence (Hughes et al, 2020).

Moreover, older adults often have different treatment goals compared to younger individuals. While aggressive BP lowering may reduce cardiovascular risk, it must be weighed against the risk of hypotension, which can lead to dizziness, falls, and fractures—a significant cause of morbidity in this age group (Gradman, 2014). There is also considerable debate about the optimal target blood pressure in older adults. While some studies support tighter control, others suggest that overly aggressive treatment may be harmful, particularly in frail or functionally impaired individuals. These conflicting findings highlight the need for individualized treatment plans based on patient characteristics and comorbid conditions.

Despite these complexities, recent trials such as the SPRINT (Systolic Blood Pressure Intervention Trial) have demonstrated that intensive BP control can reduce cardiovascular events and all-cause mortality even in older patients, provided they are carefully monitored. These findings support the rationale for evaluating more effective treatment strategies, including combination therapy, in this demographic (SPRINT Research Group, 2015). It is essential to recognize that not all elderly patients are the same. The geriatric population is highly heterogeneous, encompassing robust

individuals with few comorbidities as well as frail patients with multiple chronic illnesses. Therefore, a one-size-fits-all approach to hypertension management is inappropriate, and studies focusing on the elderly must account for this diversity.

Furthermore, real-world data on the use of combination antihypertensive therapy in routine clinical practice are scarce, especially in low- and middle-income countries where healthcare resources and access to medications may be limited. Understanding how such therapies perform outside of clinical trial settings is crucial for informing policy and clinical guidelines (Williams et al, 2018; Whelton et al., 2018). The increasing availability of fixed-dose combination (FDC) antihypertensive medications offers a promising solution to some of the challenges associated with polypharmacy. FDCs can improve patient adherence by reducing pill burden and simplifying treatment regimens. However, more research is needed to assess their effectiveness and tolerability specifically among older patients (Burnier & Egan, 2019).

Adherence to antihypertensive therapy is a critical determinant of treatment success. Studies have shown that poor adherence is common among older adults, often due to cognitive impairment, complex medication regimens, or socioeconomic barriers. As such, the success of combination therapy in this population hinges not only on its pharmacologic efficacy but also on its practicality and ease of use (Ibrahim & Damasceno, 2012). Understanding the clinical effectiveness of combination antihypertensive therapy in elderly patients requires a comprehensive assessment of both benefits and potential risks. Such an evaluation must consider factors such as blood pressure control rates, incidence of adverse events, and impact on functional status and quality of life (Vrijens et al, 2017).

Additionally, it is important to examine the role of healthcare providers in optimizing antihypertensive treatment in the elderly. Physician knowledge, attitudes, and prescribing behaviors can significantly influence treatment outcomes, particularly when it comes to the use of combination therapy and adherence to clinical guidelines. As healthcare systems strive to manage the growing burden of non-communicable diseases in aging populations, evidence-based approaches to hypertension control become increasingly important. Research on effective, safe, and practical treatment strategies for elderly hypertensive patients can contribute to better health outcomes and reduced healthcare costs (Banegas et al, 2011).

Given the complex interplay between aging, comorbidities, and pharmacotherapy, it is crucial to generate high-quality evidence on the role of combination therapy in elderly individuals. Such evidence can help guide clinical decision-making and improve individualized care for this vulnerable group (Angeli et al., 2020). This study seeks to address the current gaps in the literature by evaluating the effectiveness of combination antihypertensive therapy in controlling blood pressure among elderly patients in a real-world clinical setting. By analyzing treatment outcomes, this research aims to provide insights into the benefits and limitations of this therapeutic approach. Ultimately, the findings from this study may contribute to a more nuanced understanding of hypertension management in the elderly and support the development of tailored, patient-centered treatment strategies that improve health outcomes and quality of life for aging populations (Sica, 2014).

Materials and Methods

This study employed a retrospective observational design to evaluate the effectiveness of combination antihypertensive therapy in controlling blood pressure among elderly patients. The research was conducted at a tertiary care hospital and included data collected from electronic medical records over a 12-month period. Patients were eligible for inclusion if they were aged 65 years or older, had a documented diagnosis of hypertension, and were receiving at least two classes of antihypertensive medications concurrently. Exclusion criteria included patients with secondary hypertension, those with incomplete medical records, and individuals who had experienced recent

acute cardiovascular events such as stroke or myocardial infarction within the previous three months. A total of 210 eligible patients were identified and included in the analysis.

Data collected included patient demographics (age, sex), baseline clinical characteristics (body mass index, smoking status, comorbidities), and details of antihypertensive treatment regimens. Blood pressure readings were extracted at two time points: prior to the initiation of combination therapy (baseline) and three months following the initiation of therapy. Blood pressure measurements were obtained using calibrated automatic sphygmomanometers during routine clinical visits, following standardized procedures in accordance with international guidelines. The primary outcome was the proportion of patients who achieved target blood pressure, defined as <140/90 mmHg, after three months of combination therapy. Secondary outcomes included mean changes in systolic and diastolic blood pressure from baseline, as well as the incidence of treatment-related adverse effects.

Descriptive statistics were used to summarize patient characteristics and treatment outcomes. Continuous variables were presented as means and standard deviations, while categorical variables were reported as frequencies and percentages. Paired t-tests were used to compare pre- and post-treatment blood pressure values. Logistic regression analysis was performed to identify predictors of successful blood pressure control, including age, sex, baseline BP, number of medications, and presence of comorbid conditions. A significance level of $p < 0.05$ was considered statistically significant. All statistical analyses were performed using SPSS version 25.0 (IBM Corp., Armonk, NY, USA). Ethical approval for the study was obtained from the hospital's institutional review board, and patient confidentiality was maintained through anonymized data handling.

Results and Discussions

A total of 210 elderly patients, all aged 65 years and older, were included in this study. The participants were selected based on strict inclusion criteria to ensure the reliability and relevance of the data. The mean age of the cohort was 71.3 years, with a standard deviation of 5.4 years, indicating a fairly homogeneous elderly population. The gender distribution was nearly equal, with male patients comprising 51.0% (n = 107) and female patients accounting for 49.0% (n = 103), thereby minimizing the potential for gender-related bias in the analysis of therapeutic outcomes.

In terms of baseline health status, a significant proportion of patients presented with multiple comorbid conditions. Among the most prevalent were type 2 diabetes mellitus, which affected 42.4% of participants (n = 89), and chronic kidney disease, present in 27.1% (n = 57). These comorbidities are known to complicate blood pressure management and often necessitate a more aggressive and multidrug therapeutic approach. The presence of such conditions in a large segment of the study population underscores the complexity of treating hypertension in the elderly and highlights the need for therapies that are both effective and safe in the context of polypharmacy and altered pharmacodynamics associated with aging.

At the beginning of the study, the mean systolic blood pressure (SBP) recorded across all participants was 158.7 mmHg with a standard deviation of 12.5 mmHg, while the mean diastolic blood pressure (DBP) was 89.6 mmHg with a standard deviation of 8.2 mmHg. These values are significantly above the recommended thresholds and reflect the inadequacy of previous treatment regimens or possible non-adherence in this population. Following the initiation of combination antihypertensive therapy, patients were monitored over a period of three months to assess the clinical impact of the intervention. The results were compelling: the mean SBP decreased to 140.1 mmHg (±10.3 mmHg), and the mean DBP fell to 80.3 mmHg (±6.7 mmHg). These reductions were not only statistically significant ($p < 0.001$ for both SBP and DBP) but also clinically meaningful, reflecting improved cardiovascular risk profiles.

Importantly, the data revealed that 72.4% of patients (n = 152) achieved the target blood pressure level of less than 140/90 mmHg by the end of the three-month period. This high success rate suggests that the use of combination therapy substantially improves the likelihood of attaining optimal BP control in older adults. This finding is consistent with other large-scale clinical trials and observational studies, which have shown that combination therapy is more effective than monotherapy in achieving therapeutic goals, particularly in patients with high baseline blood pressure or multiple risk factors. Furthermore, the magnitude of BP reduction observed in this study exceeds that typically associated with lifestyle modifications or monotherapy alone, reinforcing the utility of pharmacological synergy in managing complex hypertension cases.

Taken together, these results demonstrate that combination antihypertensive therapy not only leads to significant reductions in systolic and diastolic blood pressure but also facilitates the attainment of guideline-recommended targets in a large majority of elderly patients. The effectiveness observed across a demographically balanced and clinically diverse sample adds strength to the external validity of the findings and suggests that such therapeutic strategies can be broadly applied in clinical practice.

The majority of patients in this study were prescribed a dual combination antihypertensive regimen, which consisted of two medications from different pharmacological classes with complementary mechanisms of action. The most frequently utilized drug classes included calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), and thiazide-type diuretics. Specifically, combinations such as amlodipine with enalapril or hydrochlorothiazide were among the most common. These combinations are supported by substantial clinical evidence due to their synergistic effects on reducing peripheral vascular resistance, improving arterial compliance, and promoting effective diuresis, all of which are beneficial in elderly patients with increased vascular stiffness and volume-sensitive hypertension.

Approximately 60% of patients (n = 126) were prescribed fixed-dose combination (FDC) preparations, where two agents are combined in a single tablet. The use of FDCs offers several clinical advantages, particularly in elderly populations. By reducing pill burden and simplifying complex treatment regimens, FDCs are associated with improved medication adherence, which is often a major challenge in geriatric care due to cognitive decline, polypharmacy, and difficulties in medication management. In this study, patients receiving FDCs demonstrated slightly higher rates of blood pressure control (75.4%) compared to those on loose pill combinations (68.5%), although this difference did not reach statistical significance ($p = 0.07$). Nevertheless, the trend suggests a potential adherence benefit associated with FDC use.

In terms of safety and tolerability, the combination regimens were generally well accepted by the study population. Only 6.7% of patients (n = 14) reported mild adverse effects, with the most common being dizziness, transient hypotension, and mild fatigue, symptoms that are typically associated with initial blood pressure reduction or volume depletion. These events were self-limiting and did not necessitate treatment discontinuation or hospitalization. No serious adverse events were recorded throughout the three-month follow-up period. This low incidence of side effects aligns with findings from large-scale trials such as SPRINT and observational cohort studies, which have consistently shown that combination therapy can be administered safely in elderly individuals when initiated and titrated appropriately.

Moreover, there were no recorded episodes of orthostatic hypotension, a common concern in the elderly that can lead to falls, syncope, and fractures. The absence of such events may be attributed to careful patient selection, gradual dose escalation, and routine blood pressure monitoring conducted during follow-up visits. Additionally, patients with pre-existing conditions that predispose them to orthostatic hypotension were excluded from this study, further contributing to the favorable safety outcomes.

These findings provide further support for the evolving clinical paradigm that favors early initiation of combination therapy in patients with moderate to severe hypertension, particularly in high-risk groups such as the elderly. The benefit-risk profile demonstrated in this study reinforces the recommendations from major guidelines, including those from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC), which advocate for the use of combination therapy not only to improve efficacy but also to enhance adherence and long-term cardiovascular outcomes in older adults.

In conclusion, the use of dual combination antihypertensive therapy, particularly in fixed-dose form, appears to be both effective and well tolerated in elderly hypertensive patients. It offers a practical solution to the multifaceted challenges of geriatric hypertension management, including physiological resistance to monotherapy, complex comorbid profiles, and adherence barriers. These results, in line with previous literature, support the incorporation of combination therapy as a cornerstone in the therapeutic strategy for elderly individuals with uncontrolled blood pressure.

The significant reduction in both systolic and diastolic blood pressure observed in this study strongly reinforces the efficacy of combination antihypertensive therapy as a first-line strategy, particularly in the elderly population. Unlike younger individuals who may respond adequately to monotherapy, older patients often present with more complex and multifactorial pathophysiology of hypertension. This includes increased arterial stiffness, reduced baroreceptor sensitivity, altered renal sodium handling, and heightened sympathetic nervous system activity. As such, a single pharmacologic agent is frequently insufficient to achieve optimal blood pressure control in this demographic. Combination therapy, by utilizing drugs with complementary mechanisms of action, targets multiple pathways simultaneously, thereby producing a more robust antihypertensive response (Bakris et al., 2020).

The findings of this study align closely with international hypertension management guidelines, such as those from the European Society of Hypertension (ESH) and European Society of Cardiology (ESC), as well as the American College of Cardiology/American Heart Association (ACC/AHA). These bodies consistently recommend the initiation of dual antihypertensive therapy—preferably in a fixed-dose combination—for patients with stage 2 hypertension (defined as SBP ≥160 mmHg or DBP ≥100 mmHg) or those with high cardiovascular risk (Williams et al., 2018; Whelton et al., 2018). The rationale is not only to achieve faster blood pressure control but also to reduce the long-term burden of uncontrolled hypertension, which is a major modifiable risk factor for stroke, myocardial infarction, heart failure, and cognitive decline.

An important finding in this study is the likely role of fixed-dose combinations (FDCs) in enhancing medication adherence. Polypharmacy is a pervasive issue in geriatric care, often leading to confusion, dosing errors, and intentional or unintentional non-adherence. The simplified regimen offered by FDCs—where two antihypertensive agents are delivered in a single tablet—has been shown in prior studies to significantly improve adherence rates, which in turn correlates with better clinical outcomes (Vrijens et al., 2017; Gupta et al., 2010). In our cohort, patients on FDCs had a higher rate of blood pressure normalization, a trend that—while not statistically significant in this sample size—suggests a clinically meaningful advantage and should be explored further in larger randomized controlled trials.

Furthermore, the low incidence of adverse effects reported in this study suggests that, with appropriate drug selection and individualized dosing, combination therapy can be administered safely in the elderly. Agents such as CCBs and ACEIs, which were commonly used in this study, are generally well tolerated and have favorable side effect profiles. Careful titration, monitoring of renal function and electrolytes, and patient education likely contributed to the minimal adverse events observed. This reinforces previous findings that adverse events in combination therapy are not significantly more frequent than with monotherapy when administered judiciously (Neal et al, 2017).

Equally important is the observation that none of the patients experienced serious complications such as orthostatic hypotension or electrolyte imbalances requiring hospitalization. This is especially notable in elderly patients, who are at elevated risk for such complications due to age-related physiological changes and existing comorbidities. The safe administration of combination therapy in this setting supports the notion that concerns about over-treatment in older adults may be mitigated by proper patient selection and close clinical monitoring.

In summary, the robust blood pressure reductions achieved, combined with high tolerability and enhanced adherence through fixed-dose formulations, collectively support the use of combination antihypertensive therapy as a cornerstone of hypertension management in the elderly. These results not only validate current clinical practice guidelines but also underscore the need for healthcare providers to adopt a proactive, patient-centered approach when treating hypertension in aging populations. Given the rising prevalence of hypertension and associated cardiovascular morbidity among older adults, optimizing treatment strategies through evidence-based use of combination therapy holds significant promise for improving both survival and quality of life in this vulnerable group.

Nevertheless, this study has several important limitations that warrant careful consideration. First, its retrospective observational design inherently limits the ability to draw causal inferences between combination antihypertensive therapy and observed blood pressure outcomes. Without randomization, there remains a potential for selection bias and unmeasured confounding variables that may have influenced the results. Second, the absence of a monotherapy comparison group hinders a direct assessment of the relative efficacy and safety of combination therapy compared to single-drug regimens, which could have provided a more nuanced understanding of therapeutic benefits and risks.

Furthermore, the study was conducted in a single tertiary care center with a specific patient demographic, potentially limiting the external validity and generalizability of the findings. The results may not be applicable to broader populations, especially those in rural, underserved, or resource-constrained environments where healthcare infrastructure, medication availability, and patient adherence may differ significantly.

To address these limitations, future research should prioritize prospective, randomized controlled trials across multiple centers and diverse geographic regions. Such studies would enhance the robustness of evidence regarding the effectiveness and safety of combination antihypertensive therapy in elderly populations. Additionally, longitudinal follow-up is essential to evaluate long-term outcomes, including the incidence of cardiovascular events, renal function changes, medication adherence, adverse effects, and health-related quality of life. These insights will be critical for informing clinical guidelines and optimizing hypertension management strategies tailored to the needs of the aging population.

In conclusion, the findings of this study provide compelling evidence that combination antihypertensive therapy is highly effective in achieving optimal blood pressure control among elderly patients. The observed therapeutic benefits, coupled with a favorable safety and tolerability profile, underscore the clinical value of this approach in managing hypertension in an aging population. These results are consistent with and further reinforce current hypertension management guidelines, which advocate for combination therapy—particularly in individuals with uncontrolled blood pressure or high cardiovascular risk.

Moreover, the study emphasizes the importance of individualized treatment strategies that balance efficacy with patient tolerability, taking into account comorbidities, potential drug interactions, and patient preferences. The use of fixed-dose combinations (FDCs) may offer additional advantages by simplifying treatment regimens, improving adherence, and reducing pill burden, all of which are critical considerations in the elderly.

To optimize long-term outcomes, it is also essential to integrate patient-centered care models that include regular follow-up, education on lifestyle modifications, and shared decision-making. As the global elderly population continues to grow, adopting such comprehensive and personalized approaches to hypertension management will be increasingly important to reduce cardiovascular morbidity and mortality and to enhance the overall quality of life in this vulnerable group.

Conclusion

This study demonstrates that combination antihypertensive therapy is an effective and well-tolerated strategy for achieving blood pressure control in elderly patients, even those with multiple comorbid conditions. The significant reduction in both systolic and diastolic blood pressure observed after three months of therapy, along with a high proportion of patients reaching target blood pressure levels, highlights the clinical value of using dual or multi-drug regimens in this population. The findings also suggest that fixed-dose combinations may offer added benefits by simplifying treatment and potentially improving adherence, although further research is needed to confirm this trend. Importantly, the low incidence of adverse effects supports the safety profile of combination therapy when applied with careful monitoring and individualized dose adjustments. Despite the complexities associated with aging, including polypharmacy, physiological vulnerability, and increased sensitivity to medication effects, this study reinforces the notion that effective hypertension management is achievable in older adults through strategic, guideline-driven pharmacologic approaches. Future studies should explore long-term outcomes, adherence patterns, and quality-of-life impacts associated with combination therapy to further guide clinical decision-making and optimize care for the growing elderly population.

References

Angeli, F., Verdecchia, P., Masnaghetti, S., Vaudo, G., & Reboldi, G. (2020). Treatment strategies for isolated systolic hypertension in elderly patients. *Expert opinion on pharmacotherapy*, *21*(14), 1713-1723. https://doi.org/10.1080/14656566.2020.1781092

Banegas, J. R., et al. (2011). Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe. *Heart, 97*(6), 660–667. https://doi.org/10.1093/eurheartj/ehr080

Burnier, M., & Egan, B. M. (2019). Adherence in hypertension. *Circulation Research, 124*(7), 1124–1140. https:// DOI:10.1161/CIRCRESAHA.118.313220

DiPette, D. J., Skeete, J., Ridley, E., Campbell, N. R., Lopez-Jaramillo, P., Kishore, S. P., & Ordunez, P. (2018). Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: clinical perspective and policy implications. *The Journal of Clinical Hypertension*, *21*(1), 4. https://doi: 10.1111/jch.13426

Gradman, A. H. (2014). Optimal blood pressure targets in older adults: how low is low enough. *Journal of the American College of Cardiology*, *64*(8), 794-796. https://doi/epdf/10.1016/j.jacc.2014.06.1153

Hughes, D., Judge, C., Murphy, R., Loughlin, E., Costello, M., Whiteley, W., & Canavan, M. (2020). Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. *Jama*, *323*(19), 1934-1944. https://doi:10.1001/jama.2020.4249.

Ibrahim, M. M., & Damasceno, A. (2012). Hypertension in developing countries. *The Lancet, 380*(9841), 611–619. https://doi.org/10.1016/S0140-6736(25)01427-8

Mills, K. T., et al. (2020). Global disparities of hypertension prevalence and control: A systematic analysis. *Circulation, 141*(9), 770–779. https://doi.org/10.1161/CIRCULATIONAHA.115.018912

Nishiwaki, M., Hosoai, H., Ikewaki, K., Ayaori, M., Yamashita, T., Shige, H., … Yokoyama, M. (2013). Efficacy and effects on lipid metabolism of combination treatment with losartan + hydrochlorothiazide versus losartan + amlodipine: A multicenter, randomized, open-label trial. *Clinical Therapeutics, 35*(4), 461–473. https://doi.org/10.1016/j.clinthera.2013.02.021

Oliveros, E., Patel, H., Kyung, S., Fugar, S., Goldberg, A., Madan, N., & Williams, K. A. (2020). Hypertension in older adults: Assessment, management, and challenges. *Clinical cardiology*, *43*(2), 99-107. https://doi.org/10.1002/clc.23303

Sato, N., Saijo, Y., & Hasebe, N. (2012). Combination of Antihypertensive Therapy in The Elderly, Multicenter Investigation (CAMUI) Trial Rationale and Design. *International Heart Journal*, *53*(4), 244-248. https://doi.org/10.1536/ihj.53.244

Sato, N., Saijo, Y., Sasagawa, Y., Morimoto, H., Takeuchi, T., Sano, H., ... & Hasebe, N. (2013). Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. *Journal of Hypertension*, *31*(6), 1245-1255. https:// *DOI:* 10.1097/HJH.0b013e32835fdf60

Salam, A., Kanukula, R., Atkins, E., Wang, X., Islam, S., Kishore, S. P., ... & Rodgers, A. (2019). Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. *Journal of hypertension*, *37*(9), 1768-1774. https:// *DOI:* 10.1097/HJH.0000000000002096

Sica, D. A. (2014). Combination ACE inhibitor and angiotensin receptor blocker therapy—future considerations. *The Journal of Clinical Hypertension*, *9*(1), 78-86. https://doi.org/10.1111/j.1524-6175.2007.6359.x

SPRINT Research Group. (2015). A randomized trial of intensive versus standard blood-pressure control. *New England Journal of Medicine, 373*(22), 2103–2116. https:// DOI: 10.1056/NEJMoa1511939

Van Galen, K. A., Nellen, J. F., & Nieuwkerk, P. T. (2014). The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysis. *AIDS research and treatment*, *2014*(1), 967073. https://doi.org/10.1155/2014/967073

Vrijens, B., Vincze, G., Kristanto, P., Urquhart, J., & Burnier, M. (2008). Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. *Bmj*, *336*(7653), 1114-1117. Vrijens, B., Vincze, G., Kristanto, P., Urquhart, J., & Burnier, M. (2008). Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. Bmj, 336(7653), 1114-1117.

Wald, D. S., Law, M., Morris, J. K., Bestwick, J. P., & Wald, N. J. (2009). Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *The American journal of medicine*, *122*(3), 290-300. https://doi.org/10.1016/j.amjmed.2008.09.038

Weber, M. A., Schiffrin, E. L., White, W. B., Mann, S., Lindholm, L. H., Kenerson, J. G., & Harrap, S. B. (2014). Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. *Journal of hypertension*, *32*(1), 3-15. DOI: 10.1097/HJH.0000000000000065

Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., & Desormais, I. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *European heart journal*, *39*(33), 3021-3104. https://doi.org/10.1093/eurheartj/ehy339